All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 16, 2022
Home » Authors » Donna Young

Donna Young

Articles

ARTICLES

Vermillion Raising $43M to Move from Bankruptcy to Solvency

Nov. 1, 2011
By Donna Young
No Comments
No Abstract
Read More

Novartis Snags Heart Drug with $620M Corthera Bid

Nov. 1, 2011
By Donna Young
No Comments
Novartis AG is expanding its cardiovascular disease therapy pipeline through its acquisition of San Mateo, Calif.-based biotech Corthera Inc., giving the Swiss pharma giant exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide currently in Phase III development as a treatment for acute decompensated heart failure (ADHF). (BioWorld Today)
Read More

NCI Reports Revlimid Post-SCT Results Positive; Trial Stopped

Nov. 1, 2011
By Donna Young
No Comments
No Abstract
Read More

WHO: No Pandemic Yet; Feds Warn of Scammers

Nov. 1, 2011
By Donna Young
No Comments
No Abstract
Read More

FDA Panel Calls for Cardio Studies for Diabetes Drugs

Nov. 1, 2011
By Donna Young
No Comments
No Abstract
Read More

Senators Hear Pleas for More Alzheimer's Research Funding

Nov. 1, 2011
By Donna Young
No Comments
No Abstract
Read More

FDA $2.4B Budget Includes Follow-on Biologic Pathway

Nov. 1, 2011
By Donna Young
No Comments
WASHINGTON - The Bush administration's proposed 2009 fiscal year budget for the FDA includes not only a 5.7 percent increase but a plan to seek authority to allow the agency to approve abbreviated applications for certain biologic products, or follow-on biologics. (BioWorld Today)
Read More

Acorda Shares Get Nice Bump With Positive MS Trial Results

Nov. 1, 2011
By Donna Young
No Comments
Study results showed that Acorda Therapeutics Inc.'s multiple sclerosis drug Fampridine-SR does not increase a patient's risk of developing cardiac arrhythmias, or an irregular heart beat. (BioWorld Today)
Read More

HCV Drugmaker Pharmasset to Raise $28.6M in Public Offering

Oct. 31, 2011
By Donna Young
No Comments
A week after initiating a Phase IIa study of its chronic hepatitis C virus (HCV) drug PSI-7977, Pharmasset Inc. priced a public offering of 1.6 million shares of its common stock at $18.75. (BioWorld Today)
Read More

Drugmakers Fraud Schemes; Elan, Eisai Are Latest Busted

Dec. 20, 2010
By Donna Young
No Comments
>WASHINGTON – Irish firm Elan Corp. plc is the latest company snared by the Department of Justice (DOJ) for illegally marketing drug products, with the Dublin-based company agreeing to pay about $203.5 million to resolve criminal and civil charges of off-label promotion of its epilepsy drug Zonegran (zonisamide).
Read More
View All Articles by Donna Young

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 13, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for May 13.
  • Hearing ear icon

    Cochlear to acquire rival Oticon Medical for $121M

    BioWorld MedTech
    Cochlear Ltd. will acquire Danish hearing implant company Oticon Medical A/S for AU$170 million (US$121 million) after parent company the Demant Group said it...
  • Illustration of cancer cells and immunotherapy treatment

    Former Genentech execs launch new immunotherapy biotech LTZ Therapeutics

    BioWorld
    After raising $17 million in seed funding, immunotherapy-focused biotech company, LTZ Therapeutics Inc., is announcing plans for the fledgling company whose...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing